Literature DB >> 32485216

Suitability and functional characterization of two Calu-3 cell models for prediction of drug permeability across the airway epithelial barrier.

Nadica Sibinovska1, Simon Žakelj1, Robert Roškar1, Katja Kristan2.   

Abstract

The Calu-3 cell line has been largely investigated as a physiological and pharmacological model of the airway epithelial barrier. Its suitability for prediction of drug permeability across the airway epithelia, however, has not been yet evaluated by using large enough set of model drugs. We evaluated two Calu-3 cell models (air-liquid and liquid-liquid) for drug permeability prediction based on the recent regulatory guidelines on showing suitability of in vitro permeability methods for drug permeability classification. Bidirectional permeability assays using 22 model drugs and several zero permeability markers, as well as using ABC transporter substrates were conducted. Functional activity of P-gp, but not of BCRP was revealed. The potential of the Calu-3 cells to be used as a model of the nasal epithelial barrier, despite their different anatomical origin, has been demonstrated by the obtained excellent correlation with the fully differentiated 3D human nasal epithelial model (MucilAir™) for 11 model drugs, as well as by the good correlation obtained with the human nasal epithelial cell line RPMI 2650. In addition, the permeability values determined in the two Calu-3 models correlated well with the intestinal permeability model Caco-2.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Air-liquid interface; Airway epithelial model; Calu-3; Drug permeability; Liquid-liquid interface

Mesh:

Substances:

Year:  2020        PMID: 32485216     DOI: 10.1016/j.ijpharm.2020.119484

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

1.  Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions.

Authors:  Domizia Baldassi; Bettina Gabold; Olivia Merkel
Journal:  Adv Nanobiomed Res       Date:  2021-05-06

2.  Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations.

Authors:  Nadica Sibinovska; Simon Žakelj; Jurij Trontelj; Katja Kristan
Journal:  Pharmaceutics       Date:  2022-02-06       Impact factor: 6.321

3.  A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies.

Authors:  Laura Nižić Nodilo; Ivo Ugrina; Drago Špoljarić; Daniela Amidžić Klarić; Cvijeta Jakobušić Brala; Mirna Perkušić; Ivan Pepić; Jasmina Lovrić; Vesna Saršon; Maša Safundžić Kučuk; Dijana Zadravec; Livije Kalogjera; Anita Hafner
Journal:  Pharmaceutics       Date:  2021-05-26       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.